Nivolumab versus Cabozantinib as second-line therapy in patients with advanced Renal Cell Carcinoma: a real-world comparison
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nivolumab versus Cabozantinib as second-line therapy in patients with advanced Renal Cell Carcinoma: a real-world comparison
Authors
Keywords
Cabozantinib, Immunotherapy, Nivolumab, Prognostic Factors, Renal Cell Carcinoma, Survival
Journal
Clinical Genitourinary Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-02-19
DOI
10.1016/j.clgc.2022.02.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarker-Oriented Therapy in Bladder and Renal Cancer
- (2021) Mathijs P. Scholtes et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review
- (2021) Alessandro Rizzo et al. Future Oncology
- Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma
- (2021) Pablo Álvarez Ballesteros et al. Cancers
- Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
- (2020) Roberto Iacovelli et al. Targeted Oncology
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
- (2019) Matteo Santoni et al. Cancers
- Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
- (2018) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- (2018) Claudia Allemani et al. LANCET
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
- (2018) Ilaria Grazia Zizzari et al. Cancer Immunology Research
- Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison
- (2018) Camillo Porta et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
- (2017) Bernard Escudier et al. EUROPEAN UROLOGY
- Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
- (2017) Marco Fioramonti et al. Oncotarget
- RECIST 1.1—Update and clarification: From the RECIST committee
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation